SGLT2i Use Tied to Lower Mortality in T2DM Across Ethnicities Tags Coronary artery disease SGLT-2 Inhibitor Read more about SGLT2i Use Tied to Lower Mortality in T2DM Across Ethnicities
Lp(a) Linked to Lower T2DM Risk Only at Higher HbA1c Levels Tags Coronary artery disease Heart disease hBA1c Read more about Lp(a) Linked to Lower T2DM Risk Only at Higher HbA1c Levels
Weight-Loss Efforts Declined 3 to 6 Years After T2DM Diagnosis Read more about Weight-Loss Efforts Declined 3 to 6 Years After T2DM Diagnosis
GLP-1RAs Linked to Lower MACE Risk in Dialysis With T2DM Tags Coronary artery disease GLP-1 agonists DPP-4 inhibitors Read more about GLP-1RAs Linked to Lower MACE Risk in Dialysis With T2DM
Finerenone Benefit Persisted Across Baseline Diabetes Care Goals Tags Lipoprotein(a) hBA1c GLP-1 agonists SGLT-2 Inhibitor Read more about Finerenone Benefit Persisted Across Baseline Diabetes Care Goals
T2DM Survey Found Low Sarcopenia Awareness Despite Positive Attitudes Read more about T2DM Survey Found Low Sarcopenia Awareness Despite Positive Attitudes
Transforming HF Management: SGLT2i Inhibitors Across LVEF Spectrum Tags Type 2 Diabetes with Heart Failure Read more about Transforming HF Management: SGLT2i Inhibitors Across LVEF Spectrum
Dapagliflozin Added to Valsartan Improved Cardiorenal Measures in T2DM Tags SGLT-2 Inhibitor Read more about Dapagliflozin Added to Valsartan Improved Cardiorenal Measures in T2DM
TZD and SGLT2i Outperform DPP-4i After Revascularization in T2DM Tags Myocardial infarction Peripheral vascular disease Stroke DPP-4 inhibitors Thiazolidinediones Read more about TZD and SGLT2i Outperform DPP-4i After Revascularization in T2DM
Oral Semaglutide 25 mg Matched SC Exposure in Obesity With and Without T2DM Tags GLP-1 agonists Read more about Oral Semaglutide 25 mg Matched SC Exposure in Obesity With and Without T2DM